Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Manfred Wirth

Showing results (61-70 of 96) with videos related to

Pageof 10
Sort By:
European Urology|May 17, 2019
Structured Population-based Prostate-specific Antigen Screening for Prostate Cancer: The European Association of Urology Position in 2019Giorgio Gandaglia, Peter Albers, Per-Anders Abrahamsson, et al.
The FEBS Journal|August 28, 2025
Newly identified properties of known pharmaceuticals and myxobacterial small molecules revealed by screening for autophagy modulatorsJanine Fichtner, Yan Yan Beer, H G Mauricio Ramm, et al.
European Urology|September 30, 2019
Quality Indicators for Bladder Cancer Services: A Collaborative ReviewJeffrey J Leow, James W F Catto, Jason A Efstathiou, et al.
Clinical Genitourinary Cancer|March 18, 2020
Multicentric Analytical and Inter-observer Comparability of Four Clinically Developed Programmed Death-ligand 1 Immunohistochemistry Assays in Advanced Clear-cell Renal Cell CarcinomaUlrich Sommer, Markus Eckstein, Johannes Ammann, et al.
European Urology|September 15, 2014
Achievements and perspectives in prostate cancer phase 3 trials from genitourinary research groups in Europe: introducing the Prostate Cancer Consortium in EuropeKarim Fizazi, Per-Anders Abrahamsson, Goran Ahlgren, et al.
BJU International|September 19, 2017
Prospective comparison of transperineal magnetic resonance imaging/ultrasonography fusion biopsy and transrectal systematic biopsy in biopsy-naïve patientsAngelika Borkowetz, Boris Hadaschik, Ivan Platzek, et al.
European Urology Oncology|June 13, 2019
Automated Bone Scan Index as an Imaging Biomarker to Predict Overall Survival in the Zometa European Study/SPCG11Mariana Reza, Manfred Wirth, Teuvo Tammela, et al.
BMC Cancer|June 22, 2023
Characterization and evaluation of gene fusions as a measure of genetic instability and disease prognosis in prostate cancerCarolin Schimmelpfennig, Michael Rade, Susanne Füssel, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 13, 2009
Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96-02/AUO AP 09/95Thomas Wiegel, Dirk Bottke, Ursula Steiner, et al.
European Journal of Cancer (Oxford, England : 1990)|December 12, 2018
SWITCH II: Phase III randomized, sequential, open-label study to evaluate the efficacy and safety of sorafenib-pazopanib versus pazopanib-sorafenib in the treatment of advanced or metastatic renal cell carcinoma (AUO AN 33/11)Margitta Retz, Jens Bedke, Martin Bögemann, et al.
Pageof 10

Showing results (61-70 of 96) with videos related to

Sort By:
Pageof 10
European Urology|May 17, 2019
Structured Population-based Prostate-specific Antigen Screening for Prostate Cancer: The European Association of Urology Position in 2019Giorgio Gandaglia, Peter Albers, Per-Anders Abrahamsson, et al.
The FEBS Journal|August 28, 2025
Newly identified properties of known pharmaceuticals and myxobacterial small molecules revealed by screening for autophagy modulatorsJanine Fichtner, Yan Yan Beer, H G Mauricio Ramm, et al.
European Urology|September 30, 2019
Quality Indicators for Bladder Cancer Services: A Collaborative ReviewJeffrey J Leow, James W F Catto, Jason A Efstathiou, et al.
Clinical Genitourinary Cancer|March 18, 2020
Multicentric Analytical and Inter-observer Comparability of Four Clinically Developed Programmed Death-ligand 1 Immunohistochemistry Assays in Advanced Clear-cell Renal Cell CarcinomaUlrich Sommer, Markus Eckstein, Johannes Ammann, et al.
European Urology|September 15, 2014
Achievements and perspectives in prostate cancer phase 3 trials from genitourinary research groups in Europe: introducing the Prostate Cancer Consortium in EuropeKarim Fizazi, Per-Anders Abrahamsson, Goran Ahlgren, et al.
BJU International|September 19, 2017
Prospective comparison of transperineal magnetic resonance imaging/ultrasonography fusion biopsy and transrectal systematic biopsy in biopsy-naïve patientsAngelika Borkowetz, Boris Hadaschik, Ivan Platzek, et al.
European Urology Oncology|June 13, 2019
Automated Bone Scan Index as an Imaging Biomarker to Predict Overall Survival in the Zometa European Study/SPCG11Mariana Reza, Manfred Wirth, Teuvo Tammela, et al.
BMC Cancer|June 22, 2023
Characterization and evaluation of gene fusions as a measure of genetic instability and disease prognosis in prostate cancerCarolin Schimmelpfennig, Michael Rade, Susanne Füssel, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 13, 2009
Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96-02/AUO AP 09/95Thomas Wiegel, Dirk Bottke, Ursula Steiner, et al.
European Journal of Cancer (Oxford, England : 1990)|December 12, 2018
SWITCH II: Phase III randomized, sequential, open-label study to evaluate the efficacy and safety of sorafenib-pazopanib versus pazopanib-sorafenib in the treatment of advanced or metastatic renal cell carcinoma (AUO AN 33/11)Margitta Retz, Jens Bedke, Martin Bögemann, et al.
Pageof 10